Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Post by MrMugsyon May 20, 2022 10:00am
189 Views
Post# 34698021

OK - what we've been discussing for a while here ... ENDO

OK - what we've been discussing for a while here ... ENDOThe floor is breaking away and finally everyone else is seeing the disaster that is ENDO.
Not sure why analysts were still giving this company growth targets on share price - guess I'll never understand that.  Share price at 56 cents - might as well be zero.

------------------------------------

  • Endo International (NASDAQ:ENDP) has begun negotiations with its lenders and senior bondholders seeking a possible reorganization of more than $8 billion of its debt, The Wall Street Journal reported on Wednesday, citing people familiar with the matter.   (Seeking Alpha)
------------------------

Make no mistake - not saying GUD will buy the 69 drugs selling in Canada under the International banner - but - I'm sure they are sniffing like no one has sniffed before.  Being able to say they united Paladin (CDN assets) with Knight assets would be the funniest thing I've ever seen.

The assets are only worth $100M (USD) in annual sales - if that - but no one knows how those assets could get back on a growth curve like our friend Samira - team has been intimate with those drugs.  It just might not be worth her while, unless the price was right.

Hahaha !  Funny how badly ENDO blew the whole thing up.
<< Previous
Bullboard Posts
Next >>